Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Q 601

Next Previous
Drug Profile

Q 601

Alternative Names: Q-601

Latest Information Update: 31 Mar 2020

Print Profile Download Citation

At a glance

  • Originator Qurient Co
  • Class COVID-19 vaccines; Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Influenza virus infections
  • Research COVID 2019 infections

Most Recent Events

  • 23 Mar 2020 Q 601 is available for licensing as of 23 Mar 2020. www.qurient.com
  • 23 Mar 2020 Early research in COVID-2019 infections in South Korea (PO)
  • 23 Mar 2020 Preclinical trials in Influenza virus infections in South Korea (PO)

Development Overview

Introduction

Q 601 is an oral, heterologus vaccine being developed by Qurient Therapeutics for the prevention of influenza and COVID-2019 infections. Preclinical development is underway in South Korea.

Qurient Therapeutics is looking for partners to develop vaccine for COVID-2019 infections.

Key Development Milestones

In March 2020, Qurient Therapeutics reported that oral administration of Q 601 immunized against avian flu increased the survival rates in mice [1] .

Drug Properties & Chemical Synopsis

  • Route of administration PO
  • Formulation unspecified
  • Class COVID-19 vaccines, Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-B (Influenza vaccines)

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7E1 (Influenza vaccines)

    J7E9 (All other viral vaccines)

Development Status

Summary Table

Download Data (CSV)
Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Research South Korea PO / unspecified Qurient Co 23 Mar 2020
Influenza virus infections - Prevention Preclinical South Korea PO / unspecified Qurient Co 23 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Qurient Co Originator South-Korea
Qurient Co Owner South-Korea

Licensing Availability

Licensing Organisation Available Indication Available Phase Region Date
Qurient Co - Unspecified - 23 Mar 2020

Scientific Summary

Pharmacodynamics

Summary

In preclinical studies, oral administration of Q 601 to mice immunized against avian flu increased survival rate by over 90% [1] .

Development History

Event Date Update Type Comment
23 Mar 2020 Licensing Status Q 601 is available for licensing as of 23 Mar 2020. www.qurient.com [1] Updated 31 Mar 2020
23 Mar 2020 Phase Change Early research in COVID-2019 infections in South Korea (PO) [1] Updated 31 Mar 2020
23 Mar 2020 Phase Change - Preclinical Preclinical trials in Influenza virus infections in South Korea (PO) [1] Updated 31 Mar 2020
23 Mar 2020 Scientific Update Pharmacodynamics data from preclinical studies in Influenza virus infections released by Qurient Therapeutics [1] Updated 31 Mar 2020

References

  1. Curient, antiviral immune activity 'Q601' "flu vaccine effect up".

    Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG
Legal
Back to top